Made me laugh Blip-cu, even if hopelessly optimistic. There's many a slip betwixt mouse and human lip (or anywhere else for that matter). Here's hoping the clinical trial results are terrific and we find a suitable partner on reasonable terms to fund the long road to a vaccine. In the meantime I'm hoping the turnaround in CC production efficiency and revised strategy will help the company get on the road to being cash-positive (or at least a manageable cash-burn) in the medium term.
HSV-2 Vax Results, page-19
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.550(5.12%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.73 | $10.73 | $10.15 | $109.7K | 10.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 490 | $10.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 911 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |